Minerva Neurosciences, Inc. — FY 2015 Form 10-K
Reporting period: Fiscal year ended December 31, 2015. The filing also provides unaudited fourth-quarter results. Minerva is a clinical-stage biopharmaceutical company developing CNS therapies; it had no approved products and generated no revenue.
Financial performance and liquidity
| Metric | FY 2015 | FY 2014 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development | $18.5 million | $42.9 million |
| General and administrative | $7.6 million | $12.0 million |
| Operating loss | $26.1 million | $54.9 million |
| Net loss | $27.1 million | $56.9 million |
| Basic and diluted loss per share | $1.16 | $4.47 |
| Net cash used in operating activities | $24.3 million | $36.0 million |
For Q4 2015, unaudited operating loss was $8.2 million, net loss was $8.4 million and loss per share was $0.34. Margins are not meaningful because the company had no revenue.
- At December 31, 2015, cash and cash equivalents were $14.3 million and marketable securities were $17.9 million, or $32.2 million combined. Current assets were $33.5 million and current liabilities were $5.3 million.
- Cash flows in 2015 were $(24.3) million from operations, $(18.3) million from investing and $38.3 million from financing; cash and cash equivalents decreased $4.3 million. Investing outflows mainly reflected purchases of marketable securities.
- Debt comprised $10.0 million of Term A loans; the balance-sheet carrying amount was approximately $9.9 million, including current and noncurrent portions. The loans bear 7.05% interest, are secured by substantially all assets other than intellectual property, and mature August 1, 2018. Interest-only payments were extended through August 1, 2016, followed by 24 months of principal and interest payments.
- Management estimated that year-end liquidity plus approximately $17.5 million of gross warrant-exercise proceeds received in January and February 2016 would fund operations into Q2 2017. This is a management estimate, not a guarantee; the company expects to need substantial additional funding.
Changes versus the prior year
Reported net loss narrowed by $29.8 million. The decline in reported R&D expense largely reflected the $22.0 million Janssen license fee recognized in 2014 and lower noncash stock-based compensation. Excluding that license fee and stock compensation, R&D program costs increased to $17.9 million from $7.8 million, driven by clinical work on MIN-101, MIN-117 and MIN-202. Lower G&A and interest expense also contributed to the smaller reported loss. The improvement in reported losses therefore does not indicate lower underlying development spending.
Pipeline, outlook and material risks
- MIN-101, schizophrenia: Phase IIb enrollment of 244 patients was completed in December 2015. The company expected core-study top-line results in Q2 2016 and planned regulatory discussions about later-stage development after reviewing trial results. The earlier Phase IIa trial did not meet its primary endpoint; the filing notes cardiac events observed in MIN-101-treated subjects.
- MIN-117, major depressive disorder: The company reported completing enrollment of 84 patients in a European Phase IIa trial in Q1 2016 and expected top-line results in Q2 2016. These are post-year-end developments and expectations stated in the filing.
- MIN-202, insomnia and adjunctive MDD: The filing reports positive top-line Phase IIa insomnia results announced in January 2016, including a positive sleep-efficiency signal at 40 mg (p<0.001); no serious adverse events were observed, with somnolence and abnormal dreams among common treatment-emergent events. It also reports March 2016 Phase Ib MDD results as well tolerated, with preliminary symptom improvements. These announcements occurred after the 2015 reporting period. Minerva shares development costs and has EU-area commercialization rights under its Janssen agreement; further payments to Janssen of up to $19.0 million through Q2 2017 were anticipated.
- MIN-301, Parkinson’s disease: Development remained preclinical, with further studies planned before an IND or equivalent filing and a Phase I study thereafter.
- Funding and execution: The company has accumulated losses of $101.8 million and expects continued losses. Its stated runway depends on the subsequent warrant proceeds and its spending plans; trial delays, negative results, regulatory requirements or inability to raise capital could require programs to be delayed, scaled back or discontinued.
- Other risks: All candidates remain unapproved and may fail in trials or not obtain regulatory approval. Minerva relies on third parties for clinical trials and manufacturing, has no sales infrastructure, and faces reimbursement, competition, intellectual-property and partner-dependence risks. It disclosed no litigation expected to have a material adverse effect and no impairment of goodwill or in-process R&D in 2015. It stated it did not currently carry product-liability insurance.
Key facts for investors to verify
- Whether subsequent filings confirm the expected MIN-101 and MIN-117 results and the planned development steps.
- Actual cash burn, warrant proceeds received, and financing needs relative to the Q2 2017 runway estimate.
- MIN-202 development spending, milestone obligations and Janssen’s opt-out, termination and royalty rights.
- Term-loan covenants, repayment schedule and eligibility to draw the additional $5 million Term B tranche, which was subject to clinical milestones and later had its deadline extended to June 30, 2016.
- Clinical safety findings, regulatory feedback, intellectual-property coverage and any subsequent impairment or material changes to the pipeline.